Sinopep-Allsino Biopharmaceutical Passes GMP Inspections for APIs in South Korea, China

MT Newswires Live

2025/02/11

Jiangsu Sinopep-Allsino Biopharmaceutical (SHA:688076) received good manufacturing practice compliance certifications from South Korea and China's Jiangsu province.

These are semaglutide and fulvestrant active pharmaceutical ingredients (API) for export to South Korea as well as epalrestat and sodium picosulfate APIs for domestic production, according to a Tuesday filing with the Shanghai bourse.

Shares of the biopharmaceutical company were down 3% in recent trade.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2510879059"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2510879059\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2510879059?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-11 16:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2510879059","market":"nz","top_or_hot":-1,"title":"Sinopep-Allsino Biopharmaceutical Passes GMP Inspections for APIs in South Korea, China","media":"MT Newswires Live","content":"<html><body><p> Jiangsu Sinopep-Allsino Biopharmaceutical (SHA:688076) received good manufacturing practice compliance certifications from South Korea and China's Jiangsu province.</p><p>These are semaglutide and fulvestrant active pharmaceutical ingredients (API) for export to South Korea as well as epalrestat and sodium picosulfate APIs for domestic production, according to a Tuesday filing with the Shanghai bourse.</p><p>Shares of the biopharmaceutical company were down 3% in recent trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sinopep-Allsino Biopharmaceutical Passes GMP Inspections for APIs in South Korea, China</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSinopep-Allsino Biopharmaceutical Passes GMP Inspections for APIs in South Korea, China\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-02-11 16:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Jiangsu Sinopep-Allsino Biopharmaceutical (SHA:688076) received good manufacturing practice compliance certifications from South Korea and China's Jiangsu province.</p><p>These are semaglutide and fulvestrant active pharmaceutical ingredients (API) for export to South Korea as well as epalrestat and sodium picosulfate APIs for domestic production, according to a Tuesday filing with the Shanghai bourse.</p><p>Shares of the biopharmaceutical company were down 3% in recent trade.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4503","symbol_name":"景林资产持仓","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2510879059","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2510879059","pubTimestamp":1739260870,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Jiangsu Sinopep-Allsino Biopharmaceutical  received good manufacturing practice compliance certifications from South Korea and China's Jiangsu province.These are semaglutide and fulvestrant active pharmaceutical ingredients  for export to South Korea as well as epalrestat and sodium picosulfate APIs for domestic production, according to a Tuesday filing with the Shanghai bourse.Shares of the biopharmaceutical company were down 3% in recent trade.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688076":"ST诺泰","BK4503":"景林资产持仓","API.AU":"Australian Pharma Industries","BK0239":"医药制造","BK4551":"寇图资本持仓","BK7103":"保健护理产品经销商","API":"声网","BK4023":"应用软件","BK4535":"淡马锡持仓"},"translate_title":"中石化全中生物制药通过中国韩国原料药GMP检查","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688076":0.9,"API.AU":1,"API":1},"content_text":"Jiangsu Sinopep-Allsino Biopharmaceutical (SHA:688076) received good manufacturing practice compliance certifications from South Korea and China's Jiangsu province.These are semaglutide and fulvestrant active pharmaceutical ingredients (API) for export to South Korea as well as epalrestat and sodium picosulfate APIs for domestic production, according to a Tuesday filing with the Shanghai bourse.Shares of the biopharmaceutical company were down 3% in recent trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}